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Non-small-cell lung cancer (NSCLC) is considered one of the
most chemoresistant tumours, and in a recent overview the
pessimism about the absolute survival benefits from chemotherapy
was underlined (Non-small Cell Lung Cancer Collaborative
Group, 1995). In particular, the meta-analysis revealed a survival
benefit of 10% at 1 year in a supportive care setting and an
increased median survival of 1.5 months in patients treated with
platinum-based chemotherapy regimens, thus emphasizing the
need for new, effective drugs and drug combination regimens.
Phase I–II clinical studies have shown that new drugs such as
gemcitabine and taxanes, used singly (Carino et al, 1997; Cortes-
Funes et al, 1997; Belani et al, 1998; Boyer et al, 1998; Natale et al,
1998; Takada et al, 1998) or in combination (Georgoulias et al,
1997a, 1997b), are active in NSCLC. Clinical protocols for cancer
chemotherapy tend to use two or more drugs rather than single
agents. Polychemotherapeutic protocol design is very complex. It is
mainly based on information derived from experimental in vitro and
in vivo studies and has favoured combinations of drugs with
complementary mechanisms of action. Conversely, drug delivery
schedules are planned without experimental preclinical information.
Preclinical studies have shown different interaction patterns of
cisplatin and gemcitabine (Peters et al, 1995; van Moorsel et al,
1998), and paclitaxel and gemcitabine (Kroep et al, 1998) activity as
a function of treatment schedule in some human tumour cell lines.
Moreover, recent studies have shown the importance of recognizing
specific perturbations induced by the different drugs on cell cycle
when designing combination or sequential therapies in order to
increase additive or synergistic effects and avoid antagonistic effects
(Hahn et al, 1993; Theodossiou et al, 1998; Zoli et al, 1999).
We investigated the cytotoxic activity of docetaxel and gem-
citabine, as well as their interaction as a function of treatment
schedule and attributed their activity to induced cell cycle pertur-
bations. With a view to translating preclinical information to clin-
ical practice, the study was conducted on two cell lines derived
from an epidermoid carcinoma and from an adenocarcinoma
obtained and characterized in our laboratory, and on primary lung
cancer cultures, considered the in vitro system which best repro-
duces the biology of clinical tumours.
MATERIALS AND METHODS
Established cell lines
The study was performed in two established NSCLC cell lines
(obtained and characterized in our laboratory) representative of
different lung cancer histotypes: the CAEP cell line derived from
an epidermoid carcinoma and the RAL cell line derived from an
adenocarcinoma (Gasperi-Campani et al, 1998). Cells were main-
tained as a monolayer at 37°C and subcultured weekly. Culture
medium was composed of Dulbecco’s modified Eagle’s medium
(DMEM)/Ham’s F12 (1:1) supplemented with fetal calf serum
(FCS; 10%), glutamine (2 mM), non-essential amino acids (1%)
and insulin (10 mg ml–1). Cells in the exponential growth phase
were used for all the experiments.
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Tumour material was obtained from 14 patients who underwent
thoracotomy for primary lung cancer: six adenocarcinomas, four
squamous cell carcinomas, three atypical and one typical carci-
noids. The areas of gross necrosis were removed from samples,
and tumour tissue was carefully minced in a small volume of
culture medium (Ham’s F12 supplemented with FCS (12%), L-
glutamine (1%), insulin (1%), polymyxin B (50U ml–1), fungizone
(5mg ml–1) and penicillin–streptomycin (50U ml–1) and reduced to
fragments of about 1mm. Samples were repeatedly passed
through hypodermic needles of decreasing diameter. The resulting
suspension was filtered through a nylon mesh (50 gauge), and a
suspension consisting of single cells or small groups of cells was
obtained. Cells were then washed two or three times in culture
medium, collected by centrifugation for 5min at 200  gand finally
resuspended in fresh medium [DCCM supplemented with FCS
(0.5%), 3,3¢-triiodo-L-thyronine (1 ´10–8 M), epidermal growth
factor (5ng ml–1), insulin (1%), glutamine (1%), hydrocortisone
(0.1mg ml–1), 17b-estradiol (1 ´10–9 M), choleric toxin
(1ng ml–1)] to perform the sulphorhodamine B (SRB) assay.
Drugs
Vinorelbine (Pierre Fabre Pharma, Milan, Italy), carboplatin
(Bristol Meyers Squibb, Latina, Italy), and docetaxel (Rhone-
Poulenc Rorer, Varese, Italy) were diluted with sterile physio-
logical solution at a concentration of 10mg ml–1, paclitaxel
(Bristol Meyers Squibb) at 6mg ml–1, gemcitabine (Lilly, Sesto
Fiorentino [FI], Italy, doxorubicin (Pharmacia, Milan, Italy) and
ifosfamide (Asta Medica, Milan, Italy) at 1mg ml–1, and cisplatin
(Iketon, Milan, Italy) at a concentration of 0.5mg ml–1, divided
into aliquots, and stored at –20°C. Drug stocks were freshly
diluted in culture medium before any experiment.
In vitro chemosensitivity assay
The SRB assay according to the method of Skehan et al (1990)
was used. Briefly, cells in the exponential phase of growth were
collected by trypsinization, counted and plated in 96-well flat-
bottomed microtitre plates (100ml of cell suspension per well).
Experiments were run in octoplet, and each experiment was
repeated three times. Eighteen to 24h after plating (a sufficient
time for exponential growth recovery), 100ml of culture medium
containing or not the specific drugs were added to the wells. At the
end of drug exposure, cells were fixed with 50% trichloroacetic
acid at 4°C (10ml per well, final concentration 10%) for 1h. After
five washes with tap water, cells were stained with 0.4% SRB
dissolved in 1% acetic acid (50ml per well) for 30min and subse-
quently washed four times with 1% acetic acid to remove unbound
stain. Plates were air-dried, and bound protein stain was solubi-
lized with 100ml of 10mMunbuffered Tris base [Tris (hydroxy-
methyl)aminomethane]. The optical density of treated cells was
read, at a wavelength of 540 or 510nm, by means of a fluores-
cence plate reader.
Single drug exposure
After preliminary experiments, drugs were used at scalar concen-
trations of 0.01, 0.1 and 1mg ml–1 for docetaxel and gemcitabine.
Cells were exposed to the single drugs for 48h.
Drug combinations
Docetaxel and gemcitabine were tested using different combina-
tion and sequence schedules. Exposure time to each of the two
drugs was 24h. Docetaxel and gemcitabine were tested at all three
concentrations (0.01, 0.1 and 1mg ml–1) in combination schemes
and when they were used as the first drug in the sequential
schemes. The lowest concentration (0.01mg ml–1) was used when
docetaxel or gemcitabine was administered as the second drug in
the sequential schemes.
Primary cell cultures were treated with the drug combination,
schedule and timing that proved most effective in the established
cell lines.
Flow cytometric analysis
For the analysis of cell cycle perturbations, exponentially growing
cells were trypsinized, rinsed and plated (3 ´105 cells per dish)
into 60-mm Petri dishes and incubated for 18–24h at 37°C before
drug exposure. Medium was aspirated from the plates, and
0.01mg ml–1 of docetaxel or gemcitabine was added to the expo-
nentially growing cells. Control dishes were cultured using the
same conditions, with comparable media changes. After a 24-h
exposure to the drugs, cells were trypsinized, washed twice
with phosphate-buffered saline and resuspended in 1ml of
4,6-diamino-2-phenylindole (DAPI). For the determination of
DNA content and S phase cell fraction in primary cultures,
surgical samples were minced in 2ml of DAPI for 3min. Cells
from cell lines and human tumours were then filtered through a
disposable 40-mm filter assembly (RATCOM, Inc., Miami, FL,
USA). Human lymphocytes were utilized as internal standard. For
every sample, 30000 cells were analysed by flow cytometry
(RATCOM), and the data obtained were elaborated using Modfit
(DNA Modeling System) software.
Statistical analysis
To quantify deviations from additive effects induced by the sequen-
tial administration of two drugs, a statistical Student’s t-test was
employed (Drewinko et al, 1976). For a given drug dose, we deter-
mined a surviving fraction (Sf) of cells: SfA for the first drug used
in the sequential schemes and SfB for the second. Following
combined administration, we determined SfAB. Additivity held,
resulting in SfAB = SfA ´SfB, so that our estimate of deviation
from additivity was the quantity SfAB – (SfA ´SfB). The ratio of
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Table 1Cytotoxic effect of drugs on CAEP and RAL cell lines
Drugs Concentrations (mg ml–1) Mean IC50 (mg ml–1)a
CAEP RAL
Doxetaxel 0.01, 0.1, 1 0.030 ±0.01 0.085 ±0.01
Gemcitabine 0.01, 0.1, 1 0.034 ±0.0090.530 ±0.10
Navelbine 0.01, 0.1, 1 0.037 ±0.01 Not reached
Paclitaxel 0.01, 0.1, 1 0.360 ±0.12 0.833 ±0.06
Doxorubicin 0.01, 0.1, 1 Not reached Not reached
Cisplatin 1, 2, 3 Not reached Not reached
Ifosfamide 1, 2, 3 Not reached Not reached
Carboplatin 2, 4, 6 Not reached Not reached
aAfter a 48-h treatment.differences between observed versus expected survival and the
square root of the relative variances for all drug combinations
examined were, in fact, distributed normally, with the average
equalling 0 and the variance equalling 1. The results obtained were
defined according to the following criteria: SfAB = SfA ´ SfB indi-
cated an additive effect, SfAB < SfA ´ SfB, a synergistic effect, and
SfAB > SfA ´ SfB, an antagonistic effect. In drug combination
studies, the performance index (PI) statistic model was used to
evaluate type of interaction (Drewinko et al, 1976).
RESULTS
Established cell lines
The CAEP cell line was generally more sensitive to all the drugs
than the RAL cell line. In particular, of the eight tested drugs,
docetaxel and gemcitabine were the two most effective in both cell
lines (Table 1).
The 24-h treatment with docetaxel followed by 24-h with gem-
citabine (Figure 1) produced only a weak synergistic interaction in
the RAL cell line (PI = 1.16) but a strong synergism in the CAEP
cell line (PI = 1.38). The synergistic interaction following the
sequence was further increased by a 48-h washout in between the
two-drug treatments in RAL cells (PI = 1.65) and even more so in
the most sensitive cell line, CAEP (PI = 2.6) (Figure 1).
The sequential scheme of a 24-h treatment with gemcitabine
immediately followed by docetaxel produced (Figure 2) a weak
synergistic effect only in the RAL cell line (PI = 1.15). The syner-
gistic interaction disappeared when washout periods of 24 or 48 h
in between the two-drug treatments were adopted (Figure 2).
The simultaneous administration of docetaxel and gemcitabine
induced (Figure 3) an antagonistic interaction in both cell lines at all
docetaxel concentrations. The antagonistic effect was consistently
observed when a single concentration of docetaxel and increasing
concentrations of gemcitabine were tested (data not shown).
Cell cycle perturbations were analysed by flow cytometric
analysis in an attempt to explain the mechanism underlying the
synergistic interaction. In RAL cells, a 24-h treatment with gem-
citabine caused an increase in G0/G1 phase cells and a dramatic
decrease in the G2/M phase, which were still present at the 72-h
Docetaxel/gemcitabine in NSCLC 611
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Figure 1 Dose-response survival curves of CAEP (A and A1) and RAL (B and B1) cells exposed to: (A) docetaxel for 24 hr followed by gemcitabine 
(0.01 mg ml–1) for 24 hr; (A1) docetaxel for 24 hr followed by a 48-hr washout and then gemcitabine (0.01 mg ml–1) for 24 hr; (B) docetaxel for 24 hr followed by
gemcitabine (0.01 mg ml-1) for 24 hr; (B1) docetaxel for 24 hr followed by a 48-hr washout and then gemcitabine (0.01 mg ml–1) for 24 hr. Docetaxel, observed
survival – •• – •• – l – •• – •• –; docetaxel®gemcitabine, –––– * –––– expected survival, — — ¨ — —observed survival.washout. The S phase cell fraction decreased slightly but had
completely recovered after the 72-h washout.
In the CAEP cell line, an increase in the G0/G1 cell fraction was
also observed in concomitance with a progressive reduction in
G2/M cells, for up to 48 h, and a partial recovery starting from the
72-h washout. The S phase cell fraction was not affected (Table 2).
Docetaxel induced a characteristic cell block in the G2/M phase
after a 24-h treatment (more evident in CAEP than in RAL cells),
which increased after a 24-h washout and progressively recovered
within 72 h at the pre-wash levels (Table 3).
Primary cell cultures
The antiproliferative effect of the most effective sequential treat-
ment, docetaxel ® 48-h washout ® gemcitabine, was tested in 14
primary cell cultures obtained from surgical material of untreated
lung cancer patients. Results (Table 4) showed a synergistic effect
in 11 cancers (80%), an additive effect in two and an antagonistic
effect in one case. The additive interactions were observed in a
squamous carcinoma and in a typical carcinoid lesion. The only
antagonistic effect was seen in an adenocarcinoma. In this limited
case series, the type of interaction did not appear to be related to
FCM–S phase cell fraction or DNA content.
DISCUSSION
Vinblastine, ifosfamide, cisplatin, vindesine and mitomycin, which
are among the most active conventional cytotoxic agents used in
monochemotherapy to treat NSCLC, induce objective tumour
response rates of about 15% in patients. It has been seen that the asso-
ciation of cisplatin with one of the other drugs only slightly improves
survival at 5 years (Non-small Cell Lung Cancer Collaborative
Group, 1995). Recently, new compounds have been proposed which
have raised some hopes for NSCLC patient treatment. Among the
most effective of these are the topoisomerase I poisons, topotecan and
irinotecan (which are both camptothecin derivatives), the tubulin
stabilizers such as paclitaxel and docetaxel, the new vinca alkaloid,
vinorelbine and, finally, the antimetabolite, gemcitabine. When used
as single agents, these new drugs have yielded response rates of more
than 20% (Feigal et al, 1993; Le Chevalier, 1996).
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0 0.01 0.05 1 Gem.
(mg ml–1)
0 0.01 0.05 1 Gem.
(mg ml–1)
0.01 0.05 1 Gem.
(mg ml–1)






Figure 2 Dose-response survival curves of CAEP (A and A1) and RAL (B and B1) cells exposed to: (A) gemcitabine for 24 hr followed by docetaxel 
(0.01 mg ml–1) for 24 hr; (A1) gemcitabine for 24 hr followed by a 48-hr washout and then docetaxel (0.01 mg ml–1) for 24 hr; (B) gemcitabine for 24 hr followed by
docetaxel (0.01 mg ml–1) for 24 hr; (B1) gemcitabine for 24 hr followed by a 48-hr washout and then docetaxel (0.01 mg ml–1) for 24 hr. Gemcitabine, observed
survival – •• – •• – l – •• – •• –; docetaxel®gemcitabine, –––– * –––– expected survival, — — ¨ — —observed survival.In previous studies on human breast cancer cell lines and primary
breast cancer cultures, we showed (Amadori et al, 1996) that treat-
ment with doxorubicin followed by paclitaxel was more cytotoxic
than simultaneous drug administration or the inverse sequence of
paclitaxel followed by doxorubicin. We also showed that the
sequence defined at a preclinical level actually resulted in a high
therapeutic efficacy in advanced breast cancer patients (Amadori et
al, 1996; Frassineti et al, 1997). In a further preclinical study on
human breast cancer cell lines (Zoli et al, 1999), we observed a
major therapeutic improvement using the sequence doxorubicin ®
paclitaxel ® 48-h washout ® gemcitabine. The schedule-depen-
dent activity of multidrug regimens observed by us and other
authors thus emphasizes the importance of preclinical studies
(Peters et al, 1995; Kroep et al, 1998; van Moorsel et al, 1998).
In the present study, we used two NSCLC cell lines which
reproduce a clinical situation since they proved to be highly sensi-
tive to docetaxel and gemcitabine, in agreement with results from
preclinical and phase I–II studies on NSCLC (Carino et al, 1997;
Cortes-Funes et al, 1997; Boyer, 1998; Natale et al, 1998; Takada
et al, 1998). The sequence gemcitabine ® 48-h washout ®
docetaxel produced a low synergistic effect in both cell lines. This
can, in part, be attributed to a block induced by gemcitabine in the
G0/G1 phase that recovered after 72 h. Such a block may prevent
exposure of the cells to the cytotoxic effect of docetaxel when the
drug is administered immediately or 48 h after gemcitabine treat-
ment. Conversely, the cytotoxic effect obtained with the opposite
schedule, docetaxel ® 48-h washout ® gemcitabine, produced an
evident synergistic effect in CAEP and a strong synergistic effect
in RAL cell lines. Cell cycle perturbation analysis following this
treatment schedule indicated that docetaxel produced an initial
block in the G2/M phase, thus providing a large fraction of recov-
ered synchronized cells in the G1/S boundary, which is the specific
target phase for the antimetabolite (Hertel et al, 1990; Theodossiou
et al, 1998), for the subsequent treatment with gemcitabine. It
should be pointed out that the synergistic effect was already
present at the lowest drug concentration.
Our findings are in agreement with those of Theodossiou et al
(1998), who observed an antagonistic effect of gemcitabine and
paclitaxel when administered simultaneously in the A549 lung
cancer cell line. The same study showed a slightly less than addi-
tive cytotoxic effect when gemcitabine administration preceded
that of paclitaxel, or after the inverse sequence. Conversely, using
Docetaxel/gemcitabine in NSCLC 613
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Table 2 Percentage of cells in different cell cycle phases at different times
after a 24-h treatment with gemcitabine (0.01 mg ml–1)
Cell cycle Control Times following treatment
phase samples
0 h 24 h 48 h 72 h
RAL
G0-G1 50.2 70.1 70.2 69.7 67.4
S 35.6 28.0 28.0 29.1 32.3
G2-M 14.2 1.9 1.8 1.2 0.3
Debris 9.6 23.7 5.3 5.7 8.6
CAEP
G0-G1 55.1 65.4 63.6 70.7 63.5
S 26.1 24.5 26.5 28.1 30.5
G2-M 18.8 10.1 9.9 1.2 6.0
Debris 21.6 22.4 12.2 5.7 6.4
Table 3 Percentage of cells in different cell cycle phases at different times
after a 24-h treatment with docetaxel (0.01 mg ml–1)
Cell cycle Control Times following treatment
phase samples
0 h 24 h 48 h 72 h
RAL
G0-G1 50.2 30.1 11.4 13.4 20.2
S 35.5 34.4 22.2 28.4 42.6
G2-M 14.3 35.5 66.4 58.2 37.2
Debris 10.0 17.4 58.8 64.1 57.2
CAEP
G0-G1 55.1 20.5 11.2 13.4 34.1
S 26.0 21.5 10.2 27.4 27.0
G2-M 18.9 58.0 78.6 59.2 48.9
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Figure 3 Dose-response survival curves of CAEP (A) and RAL (B) cells exposed to: docetaxel plus gemcitabine (0.01 mg ml–1) for 24 hr. Docetaxel, observed
survival – •• – •• – l – •• – •• –; docetaxel®gemcitabine, –––– * –––– expected survival, — — ¨ — —observed survival.the other taxane, docetaxel, and following the sequential treatment
docetaxel–gemcitabine, we observed a synergistic cytotoxic effect
that increased significantly when the second drug was given after a
48-h washout. This finding was confirmed in most of the primary
cultures from clinical human lung cancer tumour we used, which
represents an important step in validating preclinical results before
translating them into clinical practice (Villa et al, 1992).
The results from the present study reinforce the importance,
previously evidenced for other drugs and tumour types (Citro et al,
1991; Savini et al, 1992; Dogliotti et al, 1996; De Lena et al, 1997;
Silvestrini et al, 1997; Amadori et al, 1998; Fischel et al 1998; Van
Moorsel et al 1998, 1999; Zoli et al, 1999) of preclinical research
to define the best treatment scheduling. Considering the recently
published results (Spiridonidis et al, 1998; Georgoulias et al,
1999), which show that gemcitabine and docetaxel can be safely
used in combination, a protocol on advanced NSCLC will shortly
be activated in Italy based on the findings from the present study.
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Table 4 Cytotoxic effects of sequential treatment, docetaxel (0.01, 0.1 and 1 mg ml–1 for 24 h) followed by a 48-h washout and then gemcitabine (0.01 mg ml–1
for 24 h), observed in 14 primary lung cancer cultures
Sample Histotype Cytotoxic Performance DNA FCM-S
effect index content (%)
1 Adenocarcinoma Synergistic 2.40 Multiploid NAa
2 Adenocarcinoma Synergistic 1.55 Near-diploid 9.7
3 Adenocarcinoma Synergistic 1.46 Hyperdiploid 16.8
4 Adenocarcinoma Synergistic 1.37 Multiploid 3.8
5 Adenocarcinoma Synergistic 1.31 Multiploid NA
6 Adenocarcinoma Antagonistic 1.29 Multiploid NA
7 Squamous cell ca. Synergistic 4.03 Near-diploid 11.5
8 Squamous cell ca. Synergistic 3.53 Multiploid NA
9 Squamous cell ca. Synergistic 1.41 Near-diploid 11.1
10 Squamous cell ca. Additive – Near-diploid 11.4
11 Atypical carcinoid Synergistic 4.10 Multiploid 12.5
12 Atypical carcinoid Synergistic 1.20 Hypodiploid 4.4
13 Typical carcinoid Additive – Hypodiploid 1.0
14 Neuroendocrine with atypical carcinoid Synergistic 1.56 Hyperdiploid 14.8
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